Literature DB >> 18446520

Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Timothy W Harper1, Patrick J Brassil.   

Abstract

Reaction phenotyping studies to identify specific enzymes involved in the metabolism of drug candidates are increasingly important in drug discovery efforts. Experimental approaches used for CYP reaction phenotyping include incubations with cDNA expressed CYP enzyme systems and incubations containing specific CYP enzyme inhibitors. Since both types of experiments present specific advantages as well as known drawbacks, these studies are generally viewed as complementary approaches. Although glucuronidation pathways are also known to present potential drug-drug interaction issues as well as challenges related to their polymorphic expression, reaction phenotyping approaches for glucuronidation are generally limited to cDNA expressed systems due to lack of availability of specific UGT inhibitors. This article presents a limited review of current approaches to reaction phenotyping studies used within the pharmaceutical industry.

Mesh:

Substances:

Year:  2008        PMID: 18446520      PMCID: PMC2751464          DOI: 10.1208/s12248-008-9019-6

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  46 in total

Review 1.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

Authors:  T Iwatsubo; N Hirota; T Ooie; H Suzuki; N Shimada; K Chiba; T Ishizaki; C E Green; C A Tyson; Y Sugiyama
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

Review 2.  An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials.

Authors:  A Parkinson
Journal:  Toxicol Pathol       Date:  1996 Jan-Feb       Impact factor: 1.902

3.  Glucuronidation of all-trans-retinoic acid and 5,6-epoxy-all-trans-retinoic acid. Activation of rat liver microsomal UDP-glucuronosyltransferase activity by alamethicin.

Authors:  J M Little; P A Lehman; S Nowell; V Samokyszyn; A Radominska
Journal:  Drug Metab Dispos       Date:  1997-01       Impact factor: 3.922

4.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.

Authors:  M B Fisher; K Campanale; B L Ackermann; M VandenBranden; S A Wrighton
Journal:  Drug Metab Dispos       Date:  2000-05       Impact factor: 3.922

5.  Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine.

Authors:  C P Strassburg; S Kneip; J Topp; P Obermayer-Straub; A Barut; R H Tukey; M P Manns
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

6.  Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

Authors:  M Bourrié; V Meunier; Y Berger; G Fabre
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

7.  The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6).

Authors:  A D Rodrigues; E M Roberts
Journal:  Drug Metab Dispos       Date:  1997-05       Impact factor: 3.922

Review 8.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

9.  Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.

Authors:  A Mancy; S Dijols; S Poli; P Guengerich; D Mansuy
Journal:  Biochemistry       Date:  1996-12-17       Impact factor: 3.162

10.  Mechanism of alamethicin insertion into lipid bilayers.

Authors:  K He; S J Ludtke; W T Heller; H W Huang
Journal:  Biophys J       Date:  1996-11       Impact factor: 4.033

View more
  5 in total

Review 1.  In vitro to in vivo extrapolation for high throughput prioritization and decision making.

Authors:  Shannon M Bell; Xiaoqing Chang; John F Wambaugh; David G Allen; Mike Bartels; Kim L R Brouwer; Warren M Casey; Neepa Choksi; Stephen S Ferguson; Grazyna Fraczkiewicz; Annie M Jarabek; Alice Ke; Annie Lumen; Scott G Lynn; Alicia Paini; Paul S Price; Caroline Ring; Ted W Simon; Nisha S Sipes; Catherine S Sprankle; Judy Strickland; John Troutman; Barbara A Wetmore; Nicole C Kleinstreuer
Journal:  Toxicol In Vitro       Date:  2017-12-05       Impact factor: 3.500

2.  In vitro metabolism of piperaquine is primarily mediated by CYP3A4.

Authors:  Tina Ming-Na Lee; Liusheng Huang; Marla K Johnson; Patricia Lizak; Deanna Kroetz; Francesca Aweeka; Sunil Parikh
Journal:  Xenobiotica       Date:  2012-06-06       Impact factor: 1.908

3.  Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.

Authors:  Yaofeng Cheng; Lifei Wang; Lisa Iacono; Donglu Zhang; Weiqi Chen; Jiachang Gong; William Griffith Humphreys; Jinping Gan
Journal:  Br J Clin Pharmacol       Date:  2017-10-04       Impact factor: 4.335

Review 4.  Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1.

Authors:  Thomas M Polasek; Matthew P Doogue; John O Miners
Journal:  Ther Adv Drug Saf       Date:  2011-12

5.  How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.

Authors:  Matthew Macaluso; Alice I Nichols; Sheldon H Preskorn
Journal:  Prim Care Companion CNS Disord       Date:  2015-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.